Familial Hypercholesterolaemia Diagnosis and Management

Area of Science:

• Cardiovascular Medicine
• Genetics
• Metabolic Disorders

Background:

• Familial hypercholesterolaemia (FH) is the most prevalent monogenic disorder linked to premature coronary artery disease.
• Low-density lipoprotein (LDL) receptor gene mutations are the most common cause of FH.
• Clinical diagnosis is possible, but genetic testing confirms FH and aids cascade screening.

Purpose of the Study:

• To highlight the importance of early identification and effective management of Familial hypercholesterolaemia.
• To emphasize the high cardiovascular risk associated with FH and define treatment goals.
• To outline current and emerging therapeutic strategies for FH.

Main Methods:

• Review of clinical criteria for FH diagnosis.
• Discussion of the role of genetic testing in FH identification and cascade screening.
• Analysis of treatment guidelines and therapeutic options for FH management.

Main Results:

• Early identification and treatment of FH significantly improve patient prognosis and reduce adverse cardiovascular outcomes.
• Patients with FH are at high risk, necessitating intensive LDL cholesterol reduction to <2.6 mmol/l or at least a 50% decrease.
• Effective management involves statins, ezetimibe, colesevelam, and newly approved proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors.

Conclusions:

• Familial hypercholesterolaemia requires prompt diagnosis and aggressive lipid-lowering therapy to mitigate premature cardiovascular disease.
• Genetic testing is crucial for confirming FH and facilitating family screening.
• A multi-faceted treatment approach, including novel therapies like PCSK9 inhibitors, is essential for managing FH patients effectively.